Andrea Park

Andrea is a Chicago-based freelance writer for BioSpace. After getting her start in entertainment journalism, she has spent most of the last decade reporting on the healthcare and life sciences industries, with bylines at Fierce Medtech and Fierce Pharma, Becker’s Hospital Review and more.

The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, BioSpace reviews genetic medicines in development for the central nervous system, retinal, cardiac and neuromuscular diseases.
Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ Trodelvy showed promising results, while a complex combination by Agenus and MiNK Therapeutics failed to elicit an overall response.